April MIMS update

Some of the recent changes to the medicines landscape, with new products, indications and contraindications New Products                   Momelotinib (as dihydrochloride monohydrate) (Omjjara) and its major circulating metabolite (M21) are inhibitors of wild type Janus Kinase 1 and 2 (JAK1/JAK2) and mutant JAK2V617F, which contribute to signalling of a number of cytokines and growth factors that